Takaya Ikeda
Overview
Explore the profile of Takaya Ikeda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takemoto S, Fukuda M, Ogata R, Senju H, Sugasaki N, Nakatomi K, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2673-2682.
PMID: 39507035
Background: The prognosis of patients with lung cancer and malignant pleural effusion (MPE) caused by carcinomatous pleurisy is poor. Chemical pleurodesis is commonly performed clinically, however, often has a high...
2.
Takeda T, Nakamura D, Ikeda T
Cureus
. 2024 Oct;
16(9):e70460.
PMID: 39479150
It is well known that bevacizumab is effective against radiation necrosis in the brain (hereafter referred to as brain necrosis). Herein, we report a case of brain necrosis in a...
3.
Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, et al.
J Thorac Oncol
. 2024 Oct;
20(2):177-193.
PMID: 39395663
Introduction: SCLC has been treated as a single entity resulting in limited survival improvement. Developing effective tools for guiding appropriate therapeutic strategies is crucial. Methods: A total of 1035 SCLCs...
4.
Tomono H, Taniguchi H, Fukuda M, Ikeda T, Nagashima S, Akagi K, et al.
Thorac Cancer
. 2023 Sep;
14(28):2890-2894.
PMID: 37675546
Introduction: Combined treatment using anti-programmed death-ligand 1 antibody (anti-PD-L1) and platinum-etoposide is the current standard first-line treatment for patients with extensive-stage (ES) small cell lung cancer (SCLC). However, the best...
5.
Sakai T, Matsumoto S, Ueda Y, Shibata Y, Ikeda T, Nakamura A, et al.
J Thorac Oncol
. 2023 Aug;
18(11):1538-1549.
PMID: 37543207
Introduction: BRAF non-V600E mutations occur in 1% to 2% of NSCLCs. Because of their rarity, the clinical backgrounds and outcomes of cytotoxic chemotherapy or immunotherapy remain unclear, and no targeted...
6.
Fujiwara Y, Makihara R, Hase T, Hashimoto N, Naito T, Tsubata Y, et al.
Cancer Sci
. 2023 Jan;
114(5):2087-2097.
PMID: 36704833
The safety of osimertinib is limited in patients with severe or moderate renal impairment, or low body weight. This study aimed to investigate the safety, pharmacokinetics (PK) and recommended dose...
7.
Tamiya Y, Matsumoto S, Zenke Y, Yoh K, Ikeda T, Shibata Y, et al.
Lung Cancer
. 2023 Jan;
176:103-111.
PMID: 36634571
Introduction: KRAS G12C is an oncogenic driver mutation, accounting for approximately 14% of Caucasian patients with non-small cell lung cancer (NSCLC). Recently, several KRAS G12C-targeted drugs have been developed; however,...
8.
Akagi K, Taniguchi H, Fukuda M, Yamazaki T, Ono S, Tomono H, et al.
Thorac Cancer
. 2022 Jul;
13(16):2404-2409.
PMID: 35808894
Background: Etoposide plus cisplatin (EP) combined with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard treatment strategy for unresectable limited-disease (LD) small cell lung cancer (SCLC), which has remained...
9.
Aizawa R, Nakamura Y, Ikeda T, Aibara N, Kutsuna Y, Kurosaki T, et al.
Clin Chim Acta
. 2022 Jun;
532:84-88.
PMID: 35667476
Background: Immune checkpoint inhibitors (ICIs) have achieved important outcomes in cancer treatment. However, current clinical biomarker tests are not suitable for some patients because they require tumor tissues and have...
10.
Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, et al.
Nature
. 2021 Nov;
600(7888):319-323.
PMID: 34819663
Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-cell lung cancer (NSCLC). However, such...